Blog

The Impact Of Hormone Therapy On Heart Health | Latest Research Findings

Hormone Therapy: Hands cradling a red fabric heart against a white background.

How To Get Compounded Medication?

For a prescription of this compound, we invite you to arrange a consultation with our consulting pharmacists at Welltopia using this link. Our team will diligently evaluate the appropriateness of this formula for your needs. Following the assessment, should the formula be deemed suitable, our pharmacists will liaise with your current provider via a fax request or guide you to an appropriate provider for the prescription. Kindly be aware that any fees associated with seeing a prescriber for the prescription are separate and not included in the Pharmacist consultation fee

The impact of Hormone therapy (HT) on heart health, primarily estrogen therapy (ET), has long been a subject of debate and intrigue in the medical community.

HT has a potential impact on various aspects of health, particularly heart health. Historically, HT has been prescribed to alleviate menopausal symptoms and prevent osteoporosis.

However, concerns regarding its effects on heart health have prompted extensive research and examination.

This article delves into the intricate relationship between HT and heart health, exploring recent findings and shedding light on the current understanding of this complex topic.

Hormone therapy involves the administration of estrogen, sometimes in combination with progestin, to women experiencing menopausal symptoms or those at risk of osteoporosis.

Estrogen, a key hormone in the female reproductive system, exerts widespread effects on various tissues and organs, including the cardiovascular system and heart health.

The rationale behind HT is to supplement declining hormone levels during menopause and help against the associated symptoms.

Hormone therapy encompasses various formulations and routes of administration tailored to individual needs and preferences.

Estrogen therapy can be delivered orally, transdermally (via patches or gels), intranasally, or vaginally. 

Progestins, when indicated to oppose the effects of estrogen on the endometrium, can be administered orally or via intrauterine devices.

Micronized progesterone, a more natural form of progesterone, has gained popularity due to its potentially lower heart health risk compared to synthetic progestins.

By offering diverse options in HT, healthcare providers can tailor treatment regimens to individual patient needs while considering cardiovascular risks and benefits.

Studies on hormone replacement therapy (HRT) in women have shown various outcomes related to all-cause mortality, here are some findings.

  1. Reduced All-Cause Mortality: A cohort study in Swedish women found that HRT was associated with a reduced risk of death from all causes, with deaths in major categories of causes occurring less frequently than expected (Schairer et al., 1997).
  2. Reduced Cardiovascular Mortality: Long-term use of postmenopausal estrogen replacement therapy was associated with lower all-cause mortality, primarily through a reduction in cardiovascular disease (Ettinger et al., 1996)
  3. Recent research has highlighted potential heart health benefits associated with hormone therapy, particularly estrogen therapy.
  4. Estrogen has been shown to have vasodilatory effects, promoting arterial relaxation and improving endothelial function.
  5. Moreover, estrogen may exert anti-inflammatory and antioxidant properties, so acting against atherosclerotic processes and reducing the risk of cardiovascular events.
  6. Some studies have also suggested that HT may have a favorable impact on lipid profiles, increasing high-density lipoprotein (HDL) cholesterol levels while decreasing low-density lipoprotein (LDL) cholesterol and triglycerides.

These heart health effects contribute to a more favorable cardiovascular risk profile among women undergoing HT.

Hormone Therapy 1

Despite the potential benefits, hormone therapy is not without risks, particularly concerning heart health. 

Synthetic progestins, commonly used in combination with estrogen therapy, have been associated with adverse cardiovascular outcomes, including an increased risk of venous thromboembolism and possibly ischemic stroke.

Additionally, estrogen therapy, especially when administered orally, may elevate the risk of thrombotic events, such as deep vein thrombosis and pulmonary embolism.

Moreover, HT has been implicated in modulating the risk of cardiovascular events based on factors such as age, duration of therapy, and pre-existing cardiovascular risk factors.

Thus, careful consideration of these benefits and risks is essential when prescribing HT to menopausal women due to conflicting research findings.

Despite the controversies surrounding HT, recent research has provided more understanding of its effects on heart health.

Several studies have explored different formulations, dosages, and routes of administration to optimize cardiovascular benefits while minimizing risks. Here are some key findings from recent research.

Emerging evidence suggests that the timing of hormone therapy initiation relative to menopause may influence its cardiovascular effects.

The timing hypothesis makes clear that initiating HT closer to the onset of menopause may provide cardiovascular benefits by preserving vascular health and reducing atherosclerotic risk.

The Women’s Health Initiative trials found that HT was not associated with risk of all-cause, cardiovascular, or cancer mortality over an 18-year follow-up.

The impact of HRT (Hormone Replacement Therapy) on mortality differed based on the age and timing of initiation (Manson et al., 2017). 

Overall, the evidence suggests that hormone replacement therapy can influence mortality rates in postmenopausal women, with factors such as age at initiation and duration of therapy playing significant roles.

Hormone Therapy 2

Studies comparing different formulations of estrogen (e.g., oral, transdermal) and routes of administration have yielded interesting insights.

Transdermal estrogen delivery, either through patches or gels, has been associated with a lower risk of venous thromboembolism and possibly a more favorable lipid profile compared to oral estrogen.

Furthermore, micronized progesterone has been suggested to have a more favorable cardiovascular profile compared to synthetic progestins.

Recent research for an individualized approach to HT, takes into account a woman’s age, menopausal status, cardiovascular risk factors, and personal preferences.

Tailoring therapy based on these factors may optimize benefits while minimizing risks, thereby improving heart health outcomes.

You can book a Female hormone consultation here!

While recent research has provided valuable insights into the impact of hormone therapy on heart health, several questions and challenges remain.

Future studies should focus on explaining the underlying mechanisms, refining patient selection criteria, and optimizing treatment regimens. Additionally, long-term randomized controlled trials are needed to validate the cardiovascular benefits of HT and guide clinical practice effectively.

Hormone Therapy 3

The relationship between hormone therapy and heart health is complex and multifaceted, with recent research shedding light on the nuances of this interaction.

While controversies and challenges persist, emerging evidence suggests that hormone therapy, when appropriately prescribed and individualized, may confer cardiovascular benefits, particularly when initiated closer to menopause onset.

Moving forward, a personalized approach to hormone therapy management, informed by the latest research findings, holds promise in optimizing cardiovascular outcomes for menopausal women.

Some research findings say that hormone therapy has benefits on heart health and reduces the risk for some serious cardiovascular events.

Other research findings say that it has some potential risks and hazards, thus, careful consideration of these benefits and risks is essential when prescribing HT to menopausal women due to conflicting research findings.

Tailoring the therapy based on these factors may optimize benefits while minimizing risks, thereby improving heart health outcomes.

Estrogen has been shown to have vasodilatory effects, promoting arterial relaxation and improving endothelial function.

Also, estrogen has antioxidant properties and thus reduces the risk of some serious cardiovascular events.

Some research findings say that HT decreases low-density lipoprotein (LDL) and increases high-density lipoprotein (HDL) thus contributing to a favorable cardiovascular lipid profile.

Despite having the above benefits, hormone therapy also has some risks on heart health including an increased risk of venous thromboembolism and possibly ischemic stroke.

It also may elevate the risk of thrombotic events, such as deep vein thrombosis and pulmonary embolism.

Recent research has provided more understanding of its effects on heart health, exploring the timing hypothesis, different routes of administration, and individualized approach.

Share:

Facebook
Twitter
Pinterest
LinkedIn

Table of Contents

online pharmacist consultation

Social Media

Most Popular

New Articles